244 related articles for article (PubMed ID: 28598544)
1. Dermatological manifestations of tuberous sclerosis complex (TSC).
Ebrahimi-Fakhari D; Meyer S; Vogt T; Pföhler C; Müller CSL
J Dtsch Dermatol Ges; 2017 Jul; 15(7):695-700. PubMed ID: 28598544
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous manifestations of tuberous sclerosis complex and the paediatrician's role.
Cardis MA; DeKlotz CMC
Arch Dis Child; 2017 Sep; 102(9):858-863. PubMed ID: 28351834
[TBL] [Abstract][Full Text] [Related]
3. Tuberous sclerosis complex: A clinical diagnosis in Ethiopian patients.
Sisay B; Tadesse A; Gelaw A; Getahun D; Mulat B; Kebede W; Gebrewold Y
Medicine (Baltimore); 2024 Feb; 103(6):e37135. PubMed ID: 38335392
[TBL] [Abstract][Full Text] [Related]
4. Histological Patterns of Skin Lesions in Tuberous Sclerosis Complex: A Panorama.
Cascarino M; Leclerc-Mercier S
Dermatopathology (Basel); 2021 Jul; 8(3):236-252. PubMed ID: 34287284
[TBL] [Abstract][Full Text] [Related]
5. Dermatologic and dental aspects of the 2012 International Tuberous Sclerosis Complex Consensus Statements.
Teng JM; Cowen EW; Wataya-Kaneda M; Gosnell ES; Witman PM; Hebert AA; Mlynarczyk G; Soltani K; Darling TN
JAMA Dermatol; 2014 Oct; 150(10):1095-101. PubMed ID: 25029267
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous Manifestations of Tuberous Sclerosis.
Bakić M; Ratković M; Gledović B; Vujović B; Radunović D; Babić V; Prelević V
Acta Dermatovenerol Croat; 2018 Apr; 26(1):73-74. PubMed ID: 29782307
[TBL] [Abstract][Full Text] [Related]
7. Giant cell angiofibroma of gingiva in tuberous sclerosis complex: a case report and literature review.
Sun Q; Ryu J; Kim Y
Diagn Pathol; 2024 Mar; 19(1):50. PubMed ID: 38459589
[TBL] [Abstract][Full Text] [Related]
8. Racial differences in the dermatological manifestations of tuberous sclerosis complex and the potential effects on diagnosis and care.
Pounders AJ; Rushing GV; Mahida S; Nonyane BAS; Thomas EA; Tameez RS; Gipson TT
Ther Adv Rare Dis; 2022; 3():26330040221140125. PubMed ID: 37180419
[TBL] [Abstract][Full Text] [Related]
9. The cutaneous manifestations of tuberous sclerosis complex.
Nguyen QD; DarConte MD; Hebert AA
Am J Med Genet C Semin Med Genet; 2018 Sep; 178(3):321-325. PubMed ID: 30246432
[TBL] [Abstract][Full Text] [Related]
10. Clinical and Histologic Analysis of the Efficacy of Topical Rapamycin Therapy Against Hypomelanotic Macules in Tuberous Sclerosis Complex.
Wataya-Kaneda M; Tanaka M; Yang L; Yang F; Tsuruta D; Nakamura A; Matsumoto S; Hamasaki T; Tanemura A; Katayama I
JAMA Dermatol; 2015 Jul; 151(7):722-30. PubMed ID: 25692384
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment of cutaneous manifestations of tuberous sclerosis complex with topical 1% sirolimus cream: A prospective study of 25 patients.
Malissen N; Vergely L; Simon M; Roubertie A; Malinge MC; Bessis D
J Am Acad Dermatol; 2017 Sep; 77(3):464-472.e3. PubMed ID: 28502378
[TBL] [Abstract][Full Text] [Related]
12. Skin lesions in children with tuberous sclerosis complex: their prevalence, natural course, and diagnostic significance.
Jóźwiak S; Schwartz RA; Janniger CK; Michałowicz R; Chmielik J
Int J Dermatol; 1998 Dec; 37(12):911-7. PubMed ID: 9888331
[TBL] [Abstract][Full Text] [Related]
13. Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up.
Ebrahimi-Fakhari D; Müller CSL; Meyer S; Flotats-Bastardas M; Vogt T; Pföhler C
Dermatol Ther (Heidelb); 2017 Mar; 7(1):175-179. PubMed ID: 28181194
[TBL] [Abstract][Full Text] [Related]
14. Use of mTOR inhibitors (rapalogs) for the treatment of skin changes in tuberous sclerosis complex.
Farges D; Sigg N; Ville D; Martin L
Arch Pediatr; 2022 Dec; 29(5S):5S20-5S24. PubMed ID: 36585067
[TBL] [Abstract][Full Text] [Related]
15. Tuberous Sclerosis Complex with Gingival Enlargement in an Adolescent.
Nath S; Prakash J; Singh NN; Prajapati VK
J Coll Physicians Surg Pak; 2018 Mar; 28(3):S16-S18. PubMed ID: 29482692
[TBL] [Abstract][Full Text] [Related]
16. TuberOus SClerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patients.
Kingswood JC; d'Augères GB; Belousova E; Ferreira JC; Carter T; Castellana R; Cottin V; Curatolo P; Dahlin M; de Vries PJ; Feucht M; Fladrowski C; Gislimberti G; Hertzberg C; Jozwiak S; Lawson JA; Macaya A; Nabbout R; O'Callaghan F; Benedik MP; Qin J; Marques R; Sander V; Sauter M; Takahashi Y; Touraine R; Youroukos S; Zonnenberg B; Jansen AC;
Orphanet J Rare Dis; 2017 Jan; 12(1):2. PubMed ID: 28057044
[TBL] [Abstract][Full Text] [Related]
17. Segmental tuberous sclerosis presenting as unilateral facial angiofibromas.
Trauner MA; Ruben BS; Lynch PJ
J Am Acad Dermatol; 2003 Aug; 49(2 Suppl Case Reports):S164-6. PubMed ID: 12894111
[TBL] [Abstract][Full Text] [Related]
18. A dermatological assessment of pediatric patients with tuberous sclerosis complex (TSC).
Nunes BA; Romano AKFG; Pasa Morgan MA; Gonçalves AA; Cardozo LFM; de Almeida LGD; Haddad LA; Crippa ACS; Antoniuk SA; Abagge KT
An Bras Dermatol; 2024 Apr; ():. PubMed ID: 38658236
[TBL] [Abstract][Full Text] [Related]
19. Topical Use of Mammalian Target of Rapamycin (mTOR) Inhibitors in Tuberous Sclerosis Complex-A Comprehensive Review of the Literature.
Jóźwiak S; Sadowski K; Kotulska K; Schwartz RA
Pediatr Neurol; 2016 Aug; 61():21-7. PubMed ID: 27222056
[TBL] [Abstract][Full Text] [Related]
20. Tuberous Sclerosis.
Amorim BDB; Azulay D; Ramos-E-Silva M
Skinmed; 2021; 19(3):179-185. PubMed ID: 34303387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
